Resona Asset Management Co. Ltd. Lowers Stock Holdings in Edwards Lifesciences Corporation $EW

Resona Asset Management Co. Ltd. reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 184,684 shares of the medical research company’s stock after selling 7,421 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $15,801,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Dorato Capital Management purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $29,000. N.E.W. Advisory Services LLC boosted its stake in shares of Edwards Lifesciences by 533.9% in the fourth quarter. N.E.W. Advisory Services LLC now owns 374 shares of the medical research company’s stock valued at $32,000 after buying an additional 315 shares in the last quarter. Finally, Rakuten Securities Inc. boosted its stake in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 9,968 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $82.07, for a total value of $818,073.76. Following the completion of the transaction, the vice president directly owned 22,798 shares of the company’s stock, valued at approximately $1,871,031.86. This trade represents a 30.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 106,684 shares of company stock worth $8,811,739. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Robert W. Baird lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Piper Sandler restated an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Finally, Wells Fargo & Company lifted their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Stock Up 0.8%

EW opened at $82.85 on Thursday. The business’s fifty day moving average is $81.46 and its two-hundred day moving average is $82.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a market cap of $47.70 billion, a price-to-earnings ratio of 44.07, a PEG ratio of 2.06 and a beta of 0.87. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.